Novartis Settles With Henrietta Lacks Estate Over HeLa Cell Usage

The settlement between Novartis and the estate of Henrietta Lacks represents a major milestone in the ongoing ethical and legal reckoning within the pharmaceutical industry. Henrietta Lacks, a Black woman who died of cervical cancer in 1951, had her cells harvested without her knowledge or consent at Johns Hopkins Hospital. Those cells, known as HeLa, became the first "immortal" human cell line, capable of reproducing indefinitely in a laboratory setting. Since then, HeLa cells have been foundational to modern medicine, contributing to the development of the polio vaccine, gene mapping, and treatments for cancer and COVID-19. For decades, the Lacks family received no compensation or recognition while corporations built multi-billion dollar franchises on the back of her genetic material.

For Novartis, this settlement resolves a high-profile legal challenge that accused the company of "unjust enrichment" by profiting from biological material obtained through medical exploitation. While the financial terms of the settlement remain confidential, the agreement follows a pattern set by other industry leaders. In 2023, Thermo Fisher Scientific reached a similar settlement with the Lacks family, followed by Ultragenyx in 2024. These cases have shifted the legal landscape, moving beyond traditional statutes of limitations by focusing on the continuous commercial use of the cells as a recurring legal injury. This legal strategy effectively bypasses the decades that have passed since the original harvest, focusing instead on the present-day profits derived from the cells.

“

The settlement between Novartis and the estate of Henrietta Lacks represents a major milestone in the ongoing ethical and legal reckoning within the pharmaceutical industry.

The implications for the biotech and pharma sectors are profound. For decades, the industry operated under the assumption that biological materials, once removed from a patient, were essentially public domain or the property of the research institution. The Lacks family's legal strategy, led by prominent civil rights attorney Ben Crump, has successfully challenged this notion. Companies are now being forced to reconcile their historical reliance on HeLa cells with modern standards of informed consent and racial equity. This settlement signals that the "HeLa litigation" is far from over, as the estate continues to target other corporations that have commercialized the cell line without permission or compensation.